Robert Styperek, MD
Clinical Cardiac Electrophysiology · Rome, GANPI 1225193303
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson at 41.1% of the total. Reporting peaked in 2019 at $16,054 and has fallen 87.7% since, to $1,970 in 2025.
Across 332 payments — averaging $86.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- E.r. Squibb & Sons, L.L.C.$7K
- Abbott$5K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
- Boston Scientific$1K
- Pfizer$708
- plus $2K from 16 others
Across 93 payments — averaging $1542.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$134K
- Impulse Dynamics (USA) Inc.$9K
What the payments were for
- Speaking & faculty fees$16,80058%
- Travel & lodging$1,4855%
- Food & beverage$10,56537%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 26 | $11,863 |
| E.r. Squibb & Sons, L.L.C. | 14 | $7,239 |
| Abbott | 91 | $4,539 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 51 | $1,317 |
| Boston Scientific | 29 | $1,110 |
| Pfizer | 44 | $708 |
| Novartis | 34 | $644 |
| Medtronic(2 entities) | 15 | $532 |
| Atricure, Inc. | 3 | $200 |
| Impulse Dynamics (USA) Inc. | 4 | $194 |
| Cvrx, Inc. | 2 | $171 |
| Boehringer Ingelheim | 2 | $55 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| Cardiva Medical, Inc. | 2 | $41 |
| Merck | 2 | $38 |
| Irhythm Technologies, Inc. | 2 | $33 |
| Bardy Diagnostics, Inc. | 3 | $24 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Amgen | 1 | $17 |
| Portola Pharmaceuticals, LLC | 1 | $17 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$11,442
- ELIQUIS$7,102
- AVEIR$375
- OPTIMIZER$267
- Confirm Rx$222
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$177
- TactiCath Quartz CFA Catheter$173
- Arctic Front$152
- WATCHMAN FLX$152
- SYNERGY$149
- Quadra Allure MP RF CRT Pacemkr$137
- Watchman$130
- FlexAbility Ablation Catheter$127
- VYNDAQEL$123
- LifeVest$116
- Quartet CRT Lead$114
How this compares
$28,850 in reported general payments places this provider in the 55th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
See all clinical cardiac electrophysiology providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,763 | $1,830,570 |
| XareltoRivaroxaban | 372 | $419,906 |
| EntrestoSacubitril/Valsartan | 63 | $99,155 |
| Flecainide Acetate | 504 | $21,144 |
| FarxigaDapagliflozin Propanediol | 22 | $17,257 |
| Metoprolol Tartrate | 1,092 | $6,774 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 20 | $5,704 |
| SotalolSotalol Hcl | 211 | $4,830 |
| Amiodarone Hcl | 243 | $4,421 |
| Diltiazem Hcl | 141 | $4,412 |
| Metoprolol Succinate | 281 | $4,348 |
| Mexiletine Hcl | 40 | $3,698 |
| Warfarin Sodium | 159 | $1,995 |
| Sotalol AfSotalol Hcl | 18 | $1,439 |
| Carvedilol | 178 | $1,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $708 | $1,830,5701,763 claims |
| Johnson & JohnsonXarelto | $11,863 | $419,906372 claims |
| NovartisEntresto | $644 | $99,15563 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 93 clinical cardiac electrophysiology providers in Georgia.
Other clinical cardiac electrophysiology in Rome
- David DelurgioAtlanta$695K
- Thomas DeeringAtlanta$237K
- David NewtonSavannah$225K
- Michael LloydAtlanta$221K
- Kent NilssonAthens$198K
- Mikhael El-ChamiAtlanta$172K
- Sandeep GoyalAtlanta$153K
- Alok GambhirGainesville$146K
- Joseph PokuMacon$130K
- Anand KeniaDalton$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.